open access to scientific and medical research

Back to Journals » ClinicoEconomics and Outcomes Research » Volume 11

Original Research

Noteworthy comment: This study assessed different methods to determine whether high ICERs (incremental cost-effectiveness ratio) are caused by high drug costs, high ‘background costs’ or a combination of both and how different approaches can alter the impact of background costs on the ICER where the marginal cost-effectiveness ratio is close to, or above, the cost-effectiveness threshold.

Highly-accessed

The impact of increased post-progression survival on the cost-effectiveness of interventions in oncology

Total article views		HTML views	PDF downloads	Totals
7,066	Dovepress*	5,949+	1,526	7,475
	PubMed Central*	1,117	222	1,339
	Totals	7,066	1,748	8,814
*Since 3 May 2019

View citations on PubMed Central and Google Scholar